National Institutes of Health CPTAC researchers have uncovered new insights into tumor therapeutic resistance, heterogeneity, and immune evasion. Their work, published in Nature, leveraged several cutting-edge technologies, including spatial transcriptomics, single-nucleus RNA sequencing, and multiplexed imaging, to map the tumor microenvironment in unprecedented detail to understand how cells interact and how their location affects their behavior.…
COVID-19 is an emerging, rapidly evolving siituation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
News and Announcements
March 20, 2025
The following is the eighth entry in a Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss proteomic aspirations, the value of mentoring in science, and progress in multiple myeloma with Kiran Kumar Mangalaparthi, Ph.D., a Postdoctoral Researcher at Mayo Clinic in Rochester, Minnesota.…
March 10, 2025
Data analysis in proteogenomics has taken a marked step forward with the introduction of a new bioinformatics platform, Multiomics2Targets. This platform, developed by CPTAC researchers at the Icahn School of Medicine at Mount Sinai and published in Cell Reports Methods, integrates transcriptomics, proteomics, and phosphoproteomics data to identify potential therapeutic targets and is capable of generating detailed reports automatically. A companion protocol article describing how to use the system was also recently published in STAR Protocols.